Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valerie Glutsch

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 16, 2019
Zinc and skin: an updateValerie Glutsch, Henning Hamm, Matthias Goebeler
Dermatopathology (Basel, Switzerland)|November 22, 2022
Recurrence of a Cellular Blue Nevus with Satellitosis-A Diagnostic Pitfall with Clinical ConsequencesHermann Kneitz, Christian Rose, Valerie Glutsch, et al.
Frontiers in Immunology|December 20, 2024
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinomaValerie Glutsch, Patrick Schummer, Matthias Goebeler, et al.
Dermatopathology (Basel, Switzerland)|June 1, 2022
PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid MelanomaValerie Glutsch, Marion Wobser, Bastian Schilling, et al.
Journal for Immunotherapy of Cancer|July 14, 2019
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapyValerie Glutsch, Franziska Grän, Judith Weber, et al.
Acta Dermato-Venereologica|May 26, 2020
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate DehydrogenaseValerie Glutsch, Teresa Amaral, Claus Garbe, et al.
Cancer Immunology, Immunotherapy : CII|January 13, 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaValerie Glutsch, Hermann Kneitz, Anja Gesierich, et al.
Acta Dermato-Venereologica|January 20, 2026
Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective StudySimon Goller, Tassilo Dege, Patrick Schummer, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREGValerie Glutsch, Patrick Schummer, Hermann Kneitz, et al.
Oncogene|September 26, 2020
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expressionChristina Jessen, Julia K C Kreß, Apoorva Baluapuri, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 16, 2019
Zinc and skin: an updateValerie Glutsch, Henning Hamm, Matthias Goebeler
Dermatopathology (Basel, Switzerland)|November 22, 2022
Recurrence of a Cellular Blue Nevus with Satellitosis-A Diagnostic Pitfall with Clinical ConsequencesHermann Kneitz, Christian Rose, Valerie Glutsch, et al.
Frontiers in Immunology|December 20, 2024
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinomaValerie Glutsch, Patrick Schummer, Matthias Goebeler, et al.
Dermatopathology (Basel, Switzerland)|June 1, 2022
PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid MelanomaValerie Glutsch, Marion Wobser, Bastian Schilling, et al.
Journal for Immunotherapy of Cancer|July 14, 2019
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapyValerie Glutsch, Franziska Grän, Judith Weber, et al.
Acta Dermato-Venereologica|May 26, 2020
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate DehydrogenaseValerie Glutsch, Teresa Amaral, Claus Garbe, et al.
Cancer Immunology, Immunotherapy : CII|January 13, 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaValerie Glutsch, Hermann Kneitz, Anja Gesierich, et al.
Acta Dermato-Venereologica|January 20, 2026
Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective StudySimon Goller, Tassilo Dege, Patrick Schummer, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREGValerie Glutsch, Patrick Schummer, Hermann Kneitz, et al.
Oncogene|September 26, 2020
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expressionChristina Jessen, Julia K C Kreß, Apoorva Baluapuri, et al.
Pageof 2